REMS

News

There is enough experience with the first wave of autologous CAR-T therapies to allow strict rules ensuring their safe use to be relaxed, says FDA.

Events

Partner Content

News

AstraZeneca has launched a cost-cutting programme that will aim to slash $1.5bn a year off its costs, with the savings reinvested in R&D.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.